Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Radiotherapy

    Radiotherapy Content

    Breast Cancer, Dermatological Cancers, Diagnostics and Screening, Gastrointestinal Cancers, Gynaecological Cancers, Haematological Malignancies, Haematology, Endocrine Cancers, Paediatric Oncology, Sarcoma, Supportive Cancer Care, Soft Tissue Tumours, Neuro-oncology, Pathology, Radiology, Radiotherapy, Rare Diseases
    What’s on the horizon for continuing medical education? Insights from touchIME

    In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

    Prostate Cancer, Genitourinary Cancer, Radiotherapy
    Watch Time: 49 mins
    touchCONGRESS
    PSMA-targeted radiopharmaceuticals: An evolving approach to prostate cancer management
    CE/CME ACCREDITED Prof. Oliver Sartor, Prof. Francesco Ceci, Dr Heather Jacene Translations available:

    Three experts discuss data presented at ESMO 2023 on PSMA-targeted radiopharmaceuticals in prostate cancer.

    Learning objectives
    Learning Objectives
    • Describe potential strategies to refine selection of patients with advanced prostate cancer for treatment with PSMA-targeting radiopharmaceuticals
    • Outline how the latest data for PSMA-targeting radiopharmaceuticals may impact the timing of their use in patients with advanced prostate cancer
    • Analyse the latest data on radiopharmaceuticals in advanced prostate cancer, including combination strategies and novel agents in clinical development
    Diagnostics and Screening, Radiology, Radiotherapy
    Watch Time: 53 mins
    touchEXPERT OPINIONS
    Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
    CE/CME ACCREDITED Dr Ana Kiess, Dr Stephen Graves, Dr Jason Starr, Prof. Jorge Garcia, Dr Erik Mittra

    Following a scientific primer, the role of radiopharmaceuticals in the management of neuroendocrine tumours and prostate cancer, alongside approaches to support clinical implementation, are explored by leading experts.

    Learning objectives
    Learning Objectives
    • Describe the underlying rationale and mechanism of action for radiopharmaceuticals in adult oncology
    • Recall the different types of radiopharmaceuticals (approved and in clinical development), and their specific properties
    • Summarize the latest efficacy and safety data available for radiopharmaceuticals in the management of adult solid tumours, including potential implications for current and future clinical practice
    • Propose strategies to support integration of radiopharmaceuticals into adult oncology pathways to individualize clinical management, and ultimately, optimize patient outcomes
    Radiotherapy
    No Featured Image
    Strategies for Image-guided Proton Therapy of Cancer
    Reinhard W Schulte

    European Oncological Disease, 2007;1(2):116-8 DOI: https://doi.org/10.17925/EOH.2007.0.2.116

    During the past half century, an ongoing technological revolution in cancer imaging and radiation treatment has taken us ever closer to the goal of treating localised tumours without harming normal tissues. In his visionary 1946 paper,1 Harvard physicist Robert Wilson suggested that energetic protons could provide a nearly ideal form of radiotherapy. What makes protons […]

    Radiotherapy
    No Featured Image
    Strategies for Image-guided Proton Therapy of Cancer
    Reinhard W Schulte

    US Oncological Disease, 2007;1(1):75-7 DOI: https://doi.org/10.17925/OHR.2007.00.01.75

    Computed tomography (CT) utilizing kilovolt (kV) X-rays was not developed until the early 1970s. For the first time this imaging modality provided three-dimensional (3-D) information about tumor location and at the same time about the electron density distribution required to perform 3-D dose calculations. Therefore, it was a natural choice to develop CT-based radiation treatment […]

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup